Evidence map›Paper›PMID 34120618›Full record

ArticleHealth and quality of life outcomes2021

Enabling patient-reported outcome measures in clinical trials, exemplified by cardiovascular trials.

Theresa M Coles, Adrian F Hernandez, Bryce B Reeve, Karon Cook, Michael C Edwards, Marc Boutin, Elizabeth Bush, Arnold Degboe, Lothar Roessig, Amy Rudolph and 10 more

Abstract readLetter
In one paragraph

Article in Health and quality of life outcomes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Driving emerging technology to clinical impact.Journal of the American Dental Association (1939) · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Theresa M ColesDuke University School of Medicine, Durham, NC, USA. Theresa.coles@duke.edu.ORCID http://orcid.org/0000-0003-2941-8999
Adrian F HernandezDuke University School of Medicine, Durham, NC, USA.
Bryce B ReeveDuke University School of Medicine, Durham, NC, USA.
Karon CookNorthwestern University Feinberg School of Medicine, Chicago, IL, USA.
Michael C EdwardsArizona State University, Tempe, AZ, USA.
Marc BoutinNational Health Council, Washington, DC, USA.
Elizabeth BushEli Lilly and Company, Indianapolis, IN, USA.
Arnold DegboeAstraZeneca, Boston, MA, USA.
Lothar RoessigBayer AG, Wuppertal, Germany.
Amy RudolphNovartis, Bridgewater, NJ, USA.
Pauline McNultyJanssen, Raritan, NJ, USA.
Nikunj PatelAstraZeneca, Boston, MA, USA.
Trish Kay-MugfordNovartis, Bridgewater, NJ, USA.
Margaret VernonEvidera, Bethesda, MD, USA.
Michael WoloschakSanofi, Bridgewater, NJ, USA.
Gustavo BucheleIonis Pharmaceuticals Inc., Carlsbad, CA, USA.
John A SpertusSaint Luke's Mid America Heart Institute, Kansas City, MO, USA.
Matthew T RoeDuke University School of Medicine, Durham, NC, USA.
Denise BurySanofi, Cambridge, MA, USA.
Kevin WeinfurtDuke University School of Medicine, Durham, NC, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThere has been limited success in achieving integration of patient-reported outcomes (PROs) in clinical trials. We describe how stakeholders envision a solution to this challenge.

methodsStakeholders from academia, industry, non-profits, insurers, clinicians, and the Food and Drug Administration convened at a Think Tank meeting funded by the Duke Clinical Research Institute to discuss the challenges of incorporating PROs into clinical trials and how to address those challenges. Using examples from cardiovascular trials, this article describes a potential path forward with a focus on applications in the United States.

resultsThink Tank members identified one key challenge: a common understanding of the level of evidence that is necessary to support patient-reported outcome measures (PROMs) in trials. Think Tank participants discussed the possibility of creating general evidentiary standards depending upon contextual factors, but such guidelines could not be feasibly developed because many contextual factors are at play. The attendees posited that a more informative approach to PROM evidentiary standards would be to develop validity arguments akin to courtroom briefs, which would emphasize a compelling rationale (interpretation/use argument) to support a PROM within a specific context. Participants envisioned a future in which validity arguments would be publicly available via a repository, which would be indexed by contextual factors, clinical populations, and types of claims.

conclusionsA publicly available repository would help stakeholders better understand what a community believes constitutes compelling support for a specific PROM in a trial. Our proposed strategy is expected to facilitate the incorporation of PROMs into cardiovascular clinical trials and trials in general.

Indexed as

Patient Reported Outcome MeasuresCardiovascular DiseasesClinical Trials as TopicHumansPatient ParticipationQuality of LifeSurveys and QuestionnairesUnited StatesClinical trialsPatient-reported outcome measuresThink Tank meeting results

Identifiers

PMID34120618
PMCPMC8201736

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.